Management of precancerous cervical lesions in Iran: A cost minimizing study

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 19, 2014, Pages 8209-8213

  Nahvijou, Azin ^a   Sari, Ali Akbari ^b   Zendehdel, Kazem ^c   Marnani, Ahmad Barati ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cost minimization; Decision tree; HPV DNA testing; Iran; Pap smear

Indexed keywords

VIRUS DNA;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; COST BENEFIT ANALYSIS; DECISION TREE; DISEASE MANAGEMENT; ECONOMICS; FEMALE; FOLLOW UP; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; IRAN; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PROGNOSIS; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; COST-BENEFIT ANALYSIS; DECISION TREES; DISEASE MANAGEMENT; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IRAN; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PROGNOSIS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84908374147     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.19.8209     Document Type: Article

References (41)

1. Afrakhteh M, Khodakarami N, Moradi A, et al (2007). A study of 13315 papanicolau smear diagnoses in shohada hospital. J Family Reprod Health, 1, 74-78.
2. Andrae B, Kemetli L, Sparen P, et al (2008). Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst, 100, 622-29.
3. Andrés-Gamboa O, Chicaiza L, Garcia-Molina M, et al (2008). Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. Salud Publica Mex, 50, 276-85.
4. Anttila A, Pukkala E, Soderman B, et al (1999). Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer, 83, 59-65.
5. Arab M, Noghabaei G, Kazemi SN (2014). Comparison of crude and age-specific incidence rates of breast, ovary, endometrium and cervix cancers in Iran, 2005. Asian Pac J Cancer Pre, 15, 2461.
6. Behtash N, Nazari Z, Khaniki M, et al (2008). Liqui prep™ a new liquid based cervical cytology method in comparison with conventional Pap smear in developing counteries. ResJ Biological Sciences, 3, 627-30.
7. Berkhof J, Coupé VM, Bogaards JA, et al (2010). The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer, 127, 2147-58.
8. Bosch F, Munoz N, De Sanjose S, et al (1993). Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev, 2, 415-22.
9. Burr J M, Mowatt G, Hernández R A, et al. (2007). The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technology Assessment 2007, 11, 41.
10. Center for Disease Control and Prevention Noncomunicable Diseases Unit Cancer Office. (2012). Iranian annual of national cancer registration report 2009-2010 [Online]. Iran.
11. Chalkidou K, Marquez P, Dhillon PK, et al (2014). Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. Lancet Oncol, 15, 119-31.
12. Chawla PC, Chawla AK, Shrivastava R, et al (2014). Situation analysis of existing facilities for screening, treatment and prevention of cervical cancer in hospitals/primary health centers of delhi-NCR Region, India. Asian Pac J Cancer Prev, 15, 5475.
13. Chow IH, Tang C, You S, et al (2010). Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear forcervical cancer screening in a publicly financed health-care system. Br J Cancer, 103, 1773-82.
14. Chuck A (2010). Cost Effectiveness of 21 alternative cervical cancer screening strategies. Value in Health, 13, 169-79.
15. De Kok I M, Van Rosmalen J, Dillner J, et al (2012). Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ: British Medical Journal, 344, 1-14.
16. Doshmangir L, Rashidian a, Akbari Sari A. (2011). Unresolved issues in medical tariffs: Challenges and respective solutions to improve tariff system in Iranian health sectors. Hospital J, 10, 2-10.
17. Dzuba I G, Diaz E Y, Allen B, et al (2002). The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med, 11, 265-75.
18. Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base Lyon, France: International Agency for Research on Cancer.
19. Forman D, Bray F, Brewster D, et al (2013). Cancer incidence in five continents, Vol. X (electronic version). Lyon, IARC.
20. Franco El, Duarte-Franco E, Ferenczy L, et al (2001). Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J, 164, 1017-25.
21. Gakidou E, Nordhagen S, Obermeyer Z (2008). Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med, 5, 132.
22. Khodakarami N, Clifford GM, Yavari P, et al (2012). Human papillomavirus infection in women with and without cervical cancer in Tehran, Iran. Int J Cancer, 131, 156-61.
23. Khorasanizadeh F, Hassanloo J, Khaksar N, et al (2013). Epidemiology of cervical cancer and human papilloma virus infection among Iranian women-Analyses of national data and systematic review of the literature. Gynecol Oncol, 128, 277-81.
24. Kuhn L, Denny L, Pollack A, et al (2000). Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Nat Cancer Inst, 92, 818-25.
25. Mählck C, Jonsson H, Lenner P (1994). Pap smear screening and changes in cervical cancer mortality in Sweden. Int J Gynecol Obstetrics, 44, 267-72.
26. Malloy C, Sherris J, Herdman C (2000). HPV DNA Testing: Technical and Programmatic. Seattle, Washington, Program for Appropriate Technology in Health [http://www.popline.org], 2000 Dec. 27 p.
27. Nabandith V, Pholsena V, Mounthisone P, et al (2012). First trial of cervical cytology in healthy women of urban Laos using by self-sampling instrument. Asian Pac J Cancer Prev, 13, 4665-67.
28. Partridge EE, Abu-Rustum NR, Campos SM, et al (2010). Cervical cancer screening. J Natl Compr Canc Netw, 8, 1358-86.
29. Pity I S, Shamdeen M Y ,Wais S A (2012). Follow up of atypical squamous cell Pap Smears in Iraqi women. Asian Pac J Cancer Prev, 13, 3455-60.
30. R. N. (2014). FDA OKs HPV DNA Test for Primary Cervical Cancer Screening [Online]. Available: http://www.medscape.com/viewarticle/824114 [Accessed 24 April 2014].
31. Ries L, Eisner M, Kosary C, et al (2002). SEER Cancer Statistics Review, 1973-1999, National Cancer Institute. Bethesda, MD. Table VI-1. Available from URL: http://seer. cancer. gov/csr/1973_1999.
32. Sankaranarayanan R, Budukh A M ,Rajkumar R (2001). Effective screening programmes for cervical cancer in low-and middle-income developing countries. Bull WHO, 79, 954-62.
33. Saxena U, Sauvaget C ,Sankaranarayanan R (2012). Evidence-based screening, early diagnosis and treatment strategy of cervical cancer for national policy in low-resource countries: example of India. Asian Pac J Cancer Prev, 13, 1699-703.
34. Sengul D, Altinay S, Oksuz H, et al (2014). Population-based cervical screening outcomes in Turkey over a period of approximately nine and a half years with emphasis on results for women aged 30-34. Asian Pac J Cancer Prev: APJCP, 15, 2069.
35. Shi JF, Canfell K, Lew JB, et al (2011). Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer, 11, 239.
36. Tanprasertkul C, Sritipsukno P (2010). HPV DNA testing for cervical cancer screening: a systematic review and meta-analysis. Thammasat Medical J, 9, 15-25.
37. Treatment. M O H a M E I D O (2010). Diagnostic and treatment service tariffs in public and private sectors in 2010, Teheran, Rahavard
38. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.
39. Wang JL, Yang YZ, Dong WW, et al (2013). Application of human papillomavirus in screening for cervical cancer and precancerous lesions. Asian Pac J Cancer Prev, 14, 2979-82.
40. World B (2012). World development indicators 2012, world bank publications.
41. Zendehdel K, Sedighi Z, Hasanlou Z, Nahvijou A (2010). Improving quality of cancer registration in Iran. Part1: evaluation and comparison of cancer registration results in the country. HAKIM.